Emancipator said:My current bet (that has paid off well for myself so far, initiated early this year) is on Axsome Therapeutics. Lots of promise on their use of DXM (recreational using it is similar to Ketamine) for MDD. Phase 3 of trials start soon I believe.
With clown world a lot of normies turn to doctors to voice their displeasure with the current world and get slapped with a psych disorder, then get hopped up on old sole SSRIs (ineffective with a bunch of negative side effects). Current trend is to develop non sole-SSRI medications, with many turning to recreational drugs for inspiration, especially with the dissociates class NMDA receptor antagonist (Eskatamine being approved this year by the FDA for example)
In general am a fan of any pharma company that turns to known recreational drugs for products then come up with a way to legally sell it to "treat" something. Often they can get away with stupid high prices as well (take for example Jazz Pharma that makes billions selling Xyrem (GHB) legally for Narcolepsy, and that's extremely niche). Often can just research user reports online on various forums.
Riding it out with house money at this point.
I suspect the marijuana legalization train is a long term threat to psychiatric pharma cash cows. Psych drugs and cannabis compete for the numerous patients whose complaint takes the form "I'm miserable, and I care deeply about it." Psych drugs attack either part of that complaint with varying degrees of efficacy. Cannabis attacks the caring about it with a high degree of efficacy.
Companies working on the recreational to therapeutic niche tend to see their products hit with profound regulatory handicaps in the US. Yes, one firm got approval to market the S enantiomer of Ketamine approved for MDD, but to receive esketamine the patients have to go to an office to have it administered ensuring it will never be popular in the way blockbusters like Prozac, valproate, or Seroquel were.
If you are comfortable with the risk, keep going but do follow the news. If the Phase 3 trials are good (very probable), you may want to exit your position before approval which will likely come with absolutely oppressive rules for prescribers.